BeyondSpring
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 36
- Market Cap
- -
- Introduction
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities...
Non-small Cell Lung Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence
The non-small cell lung cancer market is driven by increasing NSCLC cases, uptake of immune checkpoint inhibitors, emerging premium therapies, and awareness of mutations. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size from 2019 to 2032 in 7MM. Key companies and therapies include EMD Serono, Merck, AstraZeneca, Bristol-Myers Squibb, and therapies like M1774, C-TIL051, and Osimertinib. FDA approvals for Opdivo and Tagrisso in 2024 highlight advancements in treatment.
Neutropenia Treatment Market to hit USD 20.8 billion by
Neutropenia treatment market to reach USD 20.8 billion by 2032, driven by cancer prevalence and chemotherapy-induced neutropenia. Rising R&D leads to new therapies like G-CSFs and oral treatments. Idiopathic neutropenia and APAC market growth are significant. Key players include Amgen, Pfizer, and Teva.
© Copyright 2024. All Rights Reserved by MedPath